Gene · 540
Papers3,770
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
781 to 800 of 3,770
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Perfecting the Life Clock: The Journey from PTO to TTFL. | Int J Mol Sci | 2023 | 36768725 | PubTator, text mining | PubMed |
| Identification of a Novel Model for Predicting the Prognosis and Immune Response Based on Genes Related to Cuproptosis and Ferroptosis in Ovarian Cancer. | Cancers (Basel) | 2023 | 36765541 | PubTator, text mining | PubMed |
| Machine learning screening for Parkinson's disease-related cuproptosis-related typing development and validation and exploration of personalized drugs for cuproptosis genes. | Ann Transl Med | 2023 | 36760248 | PubTator, text mining | PubMed |
| Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration. | Front Genet | 2023 | 36755576 | PubTator, text mining | PubMed |
| The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma. | Front Genet | 2023 | 36755568 | PubTator, text mining | PubMed |
| Construction of a cuproptosis-associated long non-coding RNA risk prediction model for pancreatic adenocarcinoma based on the TCGA database. | Medicine (Baltimore) | 2023 | 36749249 | PubTator, text mining | PubMed |
Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. | Dis Markers | 2023 | 36741910 | PubTator, text mining | PubMed |
| Challenges in Anesthesia in Wilson's Disease: A Systematic Review of the Existing Literature. | Cureus | 2023 | 36741662 | PubTator, text mining | PubMed |
| Application of attenuation coefficient in the assessment of hepatic involvement in children and adolescents with Wilson's disease. | BMC Med Imaging | 2023 | 36739392 | PubTator, text mining | PubMed |
| A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer. | Comput Struct Biotechnol J | 2023 | 36733702 | PubTator, text mining | PubMed |
| A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma. | Biomol Biomed | 2023 | 36724022 | PubTator, text mining | PubMed |
| Identification of hub genes involved in cisplatin resistance in head and neck cancer. | J Genet Eng Biotechnol | 2023 | 36715825 | PubTator, text mining | PubMed |
| A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer. | Biomed Res Int | 2023 | 36714025 | PubTator, text mining | PubMed |
| Cuproptosis-related LncRNAs signature as biomarker of prognosis and immune infiltration in pancreatic cancer. | Front Genet | 2023 | 36713077 | PubTator, text mining | PubMed |
| Incidental hypertransaminasemia in children-a stepwise approach in primary care. | Eur J Pediatr | 2023 | 36697884 | PubTator, text mining | PubMed |
| [Wilson's disease: overview]. | Med Clin (Barc) | 2023 | 36697289 | PubTator, text mining | PubMed |
| Re-evaluation of the existing health-based guidance values for copper and exposure assessment from all sources. | EFSA J | 2023 | 36694841 | PubTator, text mining | PubMed |
| Study on Computer Screening and Drug Properties of Herbs Intervening in Copper Death. | Comput Math Methods Med | 2023 | 36684691 | PubTator, text mining | PubMed |
| Copper/Zinc Ratio in Childhood and Adolescence: A Review. | Metabolites | 2023 | 36677007 | PubTator, text mining | PubMed |
| Lipidomics-Paving the Road towards Better Insight and Precision Medicine in Rare Metabolic Diseases. | Int J Mol Sci | 2023 | 36675224 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/540/papers?page=40